

# Chin Hur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3745649/publications.pdf>

Version: 2024-02-01

223  
papers

5,048  
citations

101384

36  
h-index

128067

60  
g-index

231  
all docs

231  
docs citations

231  
times ranked

6999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e51-e63.	2.4	2
2	Delivery risks and outcomes associated with grand multiparity. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 7708-7716.	0.7	3
3	Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1169-1176.	0.9	7
4	Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer. <i>Cancer</i> , 2022, 128, 819-827.	2.0	3
5	Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3693-3701.	1.1	5
6	Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 536-536.	0.8	1
7	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	0.6	4
8	Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e2148317.	2.8	17
9	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2022, 163, 163-173.	0.6	7
10	Endoscopic Balloon Dilatation Is Cost-Effective for Crohn's Disease Strictures. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5462-5471.	1.1	4
11	Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 973-982.	1.4	4
12	Databases for Gastrointestinal Clinical and Public Health Research: Have Database, Will Research. <i>Gastroenterology</i> , 2022, 163, 31-34.	0.6	0
13	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. <i>Journal of Biomedical Informatics</i> , 2022, 131, 104095.	2.5	12
14	Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. <i>Pancreatology</i> , 2022, 22, 760-769.	0.5	1
15	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16268-e16268.	0.8	0
16	Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6599-6599.	0.8	0
17	Disease Course and Outcomes of COVID-19 Among Hospitalized Patients With Gastrointestinal Manifestations. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1402-1409.e1.	2.4	28
18	Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. <i>Journal of Rheumatology</i> , 2021, 48, 454-462.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. <i>Surgery</i> , 2021, 169, 94-101.	1.0	4
20	Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. <i>Cancer Medicine</i> , 2021, 10, 684-692.	1.3	9
21	Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. <i>Genetics in Medicine</i> , 2021, 23, 576-580.	1.1	65
22	Predictors of households at risk for food insecurity in the United States during the COVID-19 pandemic. <i>Public Health Nutrition</i> , 2021, 24, 3929-3936.	1.1	86
23	Characteristics and Outcomes of Endoscopies before and during the COVID-19 Pandemic in New York. <i>Digestive Diseases</i> , 2021, 39, 663-672.	0.8	6
24	Heavy Alcohol Use Is Associated With Gastric Cancer: Analysis of the National Health and Nutrition Examination Survey From 1999 to 2010. <i>American Journal of Gastroenterology</i> , 2021, 116, 1083-1086.	0.2	12
25	International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk. <i>Gastric Cancer</i> , 2021, 24, 878-887.	2.7	6
26	Prediction of COVID-19 Social Distancing Adherence (SoDA) on the United States county-level. <i>Humanities and Social Sciences Communications</i> , 2021, 8, .	1.3	13
27	Assessment of the Acceptability and Feasibility of Using Mobile Robotic Systems for Patient Evaluation. <i>JAMA Network Open</i> , 2021, 4, e210667.	2.8	13
28	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2021, 116, 1730-1733.	0.2	1
29	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16246-e16246.	0.8	0
30	Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. <i>BMC Cancer</i> , 2021, 21, 597.	1.1	6
31	Cost-effectiveness of adjuvant chemotherapy for stage III colon cancer in the South African public healthcare setting.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18849-e18849.	0.8	0
32	Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 807-814.	0.5	10
33	Gastric Cancer:. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, xv-xviii.	0.6	0
34	Thinking green: modelling respirator reuse strategies to reduce cost and waste. <i>BMJ Open</i> , 2021, 11, e048687.	0.8	12
35	Acute Vision Loss From IgG4-Related and Bacterial Rhinosinusitis After COVID-19. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 914.	1.2	3
36	Testing and Treating <i>Helicobacter pylori</i> Infection in Individuals With Family History of Gastric Cancer is Cost-effective. <i>Gastroenterology</i> , 2021, 161, 2051-2052.e4.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Minimal Associations between Short-Term Dietary Intake and Salivary Microbiome Composition. <i>Microorganisms</i> , 2021, 9, 1739.	1.6	2
38	The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2021, 161, 487-494.e4.	0.6	15
39	Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome. <i>Gastroenterology</i> , 2021, 161, 453-462.e15.	0.6	17
40	Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2123616.	2.8	7
41	Persistent effects of the COVID-19 pandemic on diet, exercise, risk for food insecurity, and quality of life: A longitudinal study among U.S. adults. <i>Appetite</i> , 2021, 167, 105639.	1.8	24
42	Responses to Wu et al. and Wang et al.. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.2	0
43	Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data. <i>Pancreas</i> , 2021, 50, 1287-1292.	0.5	17
44	Patient and Health Care Worker Perceptions of Communication and Ability to Identify Emotion When Wearing Standard and Transparent Masks. <i>JAMA Network Open</i> , 2021, 4, e2135386.	2.8	7
45	Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. <i>JCO Global Oncology</i> , 2021, 7, 1730-1741.	0.8	3
46	Screening for Upper Gastrointestinal Malignancies in the United States—Which Immigrant Groups Should Be Considered High-Risk?. <i>Gastroenterology</i> , 2020, 158, 4-8.	0.6	6
47	Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. <i>Digestive Diseases and Sciences</i> , 2020, 65, 312-321.	1.1	2
48	Utilization of Surveillance Endoscopy for Barrett's Esophagus in Medicare Enrollees. <i>Gastroenterology</i> , 2020, 158, 773-775.e1.	0.6	5
49	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. <i>Cancer</i> , 2020, 126, 1541-1549.	2.0	12
50	Optimal Timing of Total Gastrectomy to Prevent Diffuse Gastric Cancer in Individuals With Pathogenic Variants in CDH1. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 822-829.e4.	2.4	16
51	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1961-1969.	2.4	15
52	Gender differences in prescription opioid use and misuse: Implications for men's health and the opioid epidemic. <i>Preventive Medicine</i> , 2020, 131, 105946.	1.6	33
53	Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium. <i>Gastroenterology</i> , 2020, 158, 1197-1201.	0.6	19
54	The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. <i>Obesity Science and Practice</i> , 2020, 6, 162-170.	1.0	26

#	ARTICLE	IF	CITATIONS
55	Toxicity after adjuvant therapy for stage III uterine cancer. <i>Gynecologic Oncology</i> , 2020, 159, 737-743.	0.6	2
56	Using machine learning to create prognostic systems for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 744-750.	0.6	23
57	Unsedated Colonoscopy: Impact on Quality Indicators. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3116-3122.	1.1	13
58	Delays in colonoscopy start time are associated with reductions in adenoma detection rates. <i>Digestive and Liver Disease</i> , 2020, 52, 905-908.	0.4	2
59	Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. <i>BMC Medicine</i> , 2020, 18, 257.	2.3	37
60	Where Have All the Emergencies Gone? The Impact of the COVID-19 Pandemic on Obstetric and Gynecologic Procedures and Consults at a New York City Hospital. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 28, 1411-1419.e1.	0.3	24
61	Effect of the Coronavirus 2019 Pandemic on Outcomes for Patients Admitted With Gastrointestinal Bleeding in New York City. <i>Gastroenterology</i> , 2020, 159, 1155-1157.e1.	0.6	32
62	Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5678-5686.	1.3	14
63	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	10
64	Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles. <i>JAMA Network Open</i> , 2020, 3, e1919963.	2.8	4
65	Cost effectiveness of a novel device for improving resuscitation of apneic newborns. <i>BMC Pediatrics</i> , 2020, 20, 46.	0.7	8
66	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 329-334.	0.6	4
67	Impact of quality of care on racial disparities in survival for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 396.e1-396.e13.	0.7	30
68	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020, 220, 29-34.	0.9	19
69	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. <i>PLoS ONE</i> , 2020, 15, e0231599.	1.1	38
70	Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding. <i>JAMA Network Open</i> , 2020, 3, e2026946.	2.8	25
71	Thirty-Year Risk of Cardiovascular Disease Events in Adolescents with Severe Obesity. <i>Obesity</i> , 2020, 28, 616-623.	1.5	24
72	Screening for Esophageal Squamous Cell Carcinoma. , 2019, , 291-301.e2.		0

#	ARTICLE	IF	CITATIONS
73	Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 560-562.e2.	2.4	5
74	Use of fertility preservation services in female reproductive-aged cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 328.e1-328.e16.	0.7	21
75	Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. <i>Cancer Medicine</i> , 2019, 8, 5158-5172.	1.3	21
76	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019, 18, e294-e299.	1.0	5
77	The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 66-74.	1.9	37
78	Regionalization of care for women with ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 394-400.	0.6	6
79	Effect of video monitor size on polyp detection: a prospective, randomized, controlled trial. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 254-258.e2.	0.5	3
80	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. <i>PLoS ONE</i> , 2019, 14, e0215409.	1.1	7
81	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e190047.	2.8	42
82	Race, Ethnicity, Sex, and Obesity: Is It Time to Personalize the Scale?. <i>Mayo Clinic Proceedings</i> , 2019, 94, 362-363.	1.4	29
83	A quantitative exploration of gastrointestinal bleeding in intensive care unit patients. <i>PLoS ONE</i> , 2019, 14, e0212040.	1.1	1
84	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. <i>Medicine (United States)</i> , 2019, 98, e18082.	0.4	13
85	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. <i>Cancer Medicine</i> , 2019, 8, 94-103.	1.3	54
86	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	1.9	13
87	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	2.4	24
88	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. <i>American Journal of Roentgenology</i> , 2019, 212, 596-601.	1.0	4
89	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	2.0	24
90	Low Prevalence of Suspected Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 857-863.	2.4	16

#	ARTICLE	IF	CITATIONS
91	Delay in receipt of newly prescribed oral anticancer drugs.. Journal of Clinical Oncology, 2019, 37, 6541-6541.	0.8	3
92	Use of nonclinical staff to coordinate oral anticancer drug prescriptions.. Journal of Clinical Oncology, 2019, 37, 72-72.	0.8	1
93	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2019, 37, e15517-e15517.	0.8	0
94	Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice. World Journal of Meta-analysis, 2019, 7, 406-417.	0.1	0
95	Early liver transplantation for alcoholic hepatitis: Ready for primetime?. Journal of Hepatology, 2018, 68, 380-382.	1.8	12
96	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Medicine, 2018, 7, 525-535.	1.3	136
97	Reply. Hepatology, 2018, 67, 1641-1642.	3.6	1
98	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2018, 16, 115-122.e10.	2.4	21
99	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology, 2018, 67, 837-846.	3.6	61
100	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology, 2018, 67, 2085-2095.	3.6	50
101	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 392-400.e7.	2.4	17
102	Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Cancer Medicine, 2018, 7, 6401-6410.	1.3	20
103	Analysis of factors associated with extended recovery time after colonoscopy. PLoS ONE, 2018, 13, e0199246.	1.1	4
104	Optimization of Prehospital Triage of Patients With Suspected Ischemic Stroke. Stroke, 2018, 49, 2532-2535.	1.0	25
105	Hospice use and end-of-life care among older patients with esophageal cancer. Health Science Reports, 2018, 1, e76.	0.6	16
106	Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. BMC Cancer, 2018, 18, 694.	1.1	12
107	Model to Determine the Optimal Dietary Elimination Strategy for Treatment of Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1730-1737.e2.	2.4	35
108	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology, 2018, 18, 928-934.	0.5	32

#	ARTICLE	IF	CITATIONS
109	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2880-2888.	1.1	18
110	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3060-3060.	0.8	4
111	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3096-3096.	0.8	4
112	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 56-56.	0.8	1
113	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 829-829.	0.8	0
114	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16089-e16089.	0.8	0
115	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15134-e15134.	0.8	0
116	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	2.4	20
117	Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. <i>Gastric Cancer</i> , 2017, 20, 811-824.	2.7	8
118	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	2.4	51
119	Acceptance of Surgical Treatment for Adolescent Obesity-Reply. <i>JAMA Surgery</i> , 2017, 152, 802.	2.2	0
120	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. <i>American Journal of Gastroenterology</i> , 2017, 112, 1256-1264.	0.2	45
121	Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2&6. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 711-721.	1.9	52
122	Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett's neoplasia. <i>Endoscopy International Open</i> , 2017, 05, E1128-E1135.	0.9	1
123	Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-Risk Pulmonary Embolism: A Simulation Modeling Analysis. <i>Academic Emergency Medicine</i> , 2017, 24, 1235-1243.	0.8	5
124	Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 920-928.	3.6	70
125	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. <i>JAMA Surgery</i> , 2017, 152, 136.	2.2	62
126	Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 827-837.e8.	2.4	81



#	ARTICLE	IF	CITATIONS
127	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	3.6	83
128	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. <i>Hepatology</i> , 2017, 65, 1156-1164.	3.6	76
129	The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. <i>PLoS ONE</i> , 2017, 12, e0177068.	1.1	5
130	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4117-4117.	0.8	0
131	Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18071-e18071.	0.8	0
132	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size. <i>Pancreas</i> , 2016, 45, 1062-1066.	0.5	33
133	Sa1275 Patient Decision-Making and Clinical Outcomes Following Endoscopic Therapy or Esophagectomy for Barrett's Neoplasia. <i>Gastroenterology</i> , 2016, 150, S266.	0.6	1
134	Endoscopic therapy versus surgery for T1 colon cancer: defining model clinical practice. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 995-996.	0.5	0
135	Proton Pump Inhibitors and Dementia Incidence. <i>JAMA Neurology</i> , 2016, 73, 1027.	4.5	1
136	235 Accuracy of Post-Hoc High-Resolution Microendoscopy for Diagnosis of Esophageal Squamous Cell Neoplasia. <i>Gastroenterology</i> , 2016, 150, S55.	0.6	0
137	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	3.6	126
138	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2108-2117.	1.1	67
139	Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. <i>Gut</i> , 2016, 65, 563-574.	6.1	80
140	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. <i>EBioMedicine</i> , 2015, 2, 1980-1986.	2.7	14
141	Tackling the hepatitis C cost problem: A test case for tomorrow's cures. <i>Hepatology</i> , 2015, 62, 1334-1336.	3.6	8
142	High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 5513.	1.4	13
143	The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1012-1023.	1.1	35
144	Fibroid morcellation: a shared clinical decision tool for mode of hysterectomy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 195, 122-127.	0.5	13

#	ARTICLE	IF	CITATIONS
145	Evidence-based endoscopic management of Barrett's esophagus. <i>Gastroenterology Report</i> , 2015, 3, 54-62.	0.6	3
146	Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International Trial. <i>Gastroenterology</i> , 2015, 149, 321-329.	0.6	31
147	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 665-672.e4.	2.4	42
148	Sa1025 Surgical Versus Endoscopic Management of Flat and Depressed Polyps Found in the Right Colon: Results of a Decision Analysis. <i>Gastroenterology</i> , 2015, 148, S-200.	0.6	0
149	Comparing Morbidities of Testing With a New Index: Screening Colonoscopy Versus Core-Needle Breast Biopsy. <i>Journal of the American College of Radiology</i> , 2015, 12, 295-301.	0.9	12
150	Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. <i>Radiology</i> , 2015, 275, 177-187.	3.6	34
151	Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 84-90.	2.4	11
152	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. <i>Cancer Prevention Research</i> , 2014, 7, 341-350.	0.7	27
153	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	1.1	61
154	Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1560-1566.	1.1	19
155	Mo1134 Accuracy of a High Resolution, Low-Cost Microendoscope for the Early Detection of Esophageal Squamous Cell Neoplasia: a Prospective, International, Multicenter Trial. <i>Gastroenterology</i> , 2014, 146, S-566.	0.6	1
156	Sa1822 Patient Preferences for Prevention of Esophageal Adenocarcinoma in Barrett's Esophagus, Endoscopic Ablation Versus Chemoprevention: A Prospective Multicenter Study. <i>Gastroenterology</i> , 2014, 146, S-304.	0.6	0
157	Sa1864 Aspirin Downregulates Cell Survival and mTOR Effector pS6K in Barrett's Esophagus Patients: Data From a Randomized, Double-Blind, Phase II Chemoprevention Trial. <i>Gastroenterology</i> , 2014, 146, S-315.	0.6	0
158	Sa1859 Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention With Metformin. <i>Gastroenterology</i> , 2014, 146, S-314.	0.6	0
159	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 37-44.	0.9	43
160	Garlic, Silver Bullets, and Surveillance Upper Endoscopy for Barrett's Esophagus. <i>Gastroenterology</i> , 2013, 145, 273-276.	0.6	10
161	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	0.6	195
162	Su1457 Predictors of Adenocarcinoma Development After Endoscopic Ablation Therapy for Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB330-AB331.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Responsiveness of the Testing Morbidities Index in Colonoscopy. <i>Value in Health</i> , 2013, 16, 1046-1053.	0.1	14
164	How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value. <i>Gastroenterology</i> , 2013, 144, 5-8.	0.6	17
165	Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model. <i>PLoS Medicine</i> , 2013, 10, e1001451.	3.9	30
166	Trends in esophageal adenocarcinoma incidence and mortality. <i>Cancer</i> , 2013, 119, 1149-1158.	2.0	439
167	Screening and surveillance for Barrett's esophagus. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 377-381.	1.0	16
168	Rescreening of Persons With a Negative Colonoscopy Result: Results From a Microsimulation Model. <i>Annals of Internal Medicine</i> , 2012, 157, 611.	2.0	25
169	Tu1171 Green Tea and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies. <i>Gastroenterology</i> , 2012, 142, S-765.	0.6	0
170	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 722-727.	2.4	57
171	Mo1668 Mucosal Healing is a Cost-Effective Endpoint With Biologic Therapy in Crohn's Disease - Results From a Decision Analysis. <i>Gastroenterology</i> , 2012, 142, S-654.	0.6	1
172	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 567-575.	0.6	143
173	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 917-926.e1.	0.6	58
174	318 The Cost-Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 142, S-73.	0.6	3
175	786 Effectiveness and Cost-Effectiveness of Once-Only Screening for Colorectal Cancer With Colonoscopy or Computed Tomographic Colonography. <i>Gastroenterology</i> , 2012, 142, S-141-S-142.	0.6	0
176	Tu1112 Aspirin Protective Against Barrett's Esophagus: Results of Multivariate Regression Analysis. <i>Gastroenterology</i> , 2012, 142, S-749.	0.6	1
177	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 472-480.	1.1	18
178	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2009-2017.	0.2	44
179	The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2450-2456.	1.1	38
180	Secular Trends in Patients Diagnosed with Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2010, 55, 960-966.	1.1	12

#	ARTICLE	IF	CITATIONS
181	Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 852-860.	1.1	37
182	Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. <i>Cancer</i> , 2010, 116, 2941-2953.	2.0	65
183	Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma. <i>PLoS ONE</i> , 2010, 5, e9483.	1.1	15
184	Analysis of Barriers to and Patients' Preferences for CT Colonography for Colorectal Cancer Screening in a Nonadherent Urban Population. <i>American Journal of Roentgenology</i> , 2010, 195, 393-397.	1.0	31
185	Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 33-43.	0.5	17
186	Cost-Effectiveness of Prophylactic Surgery for Duodenal Cancer in Familial Adenomatous Polyposis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2677-2684.	1.1	2
187	Upper Endoscopy in Patients with Acute Myocardial Infarction and Upper Gastrointestinal Bleeding: Results of a Decision Analysis. <i>Digestive Diseases and Sciences</i> , 2009, 54, 701-711.	1.1	26
188	Patient Preferences for the Chemoprevention of Colorectal Cancer. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2207-2214.	1.1	6
189	S1290 The Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2009, 136, A-230.	0.6	0
190	T1925 The Prevalence of Barrett's Esophagus in the US: Estimate Confirmation Using a Simulation Model and SEER Data. <i>Gastroenterology</i> , 2009, 136, A-602.	0.6	0
191	T1884 Temporal Trends in Patients Newly Diagnosed with Barrett's Esophagus in a Single-Center Cohort, 1997-2007. <i>Gastroenterology</i> , 2009, 136, A-593.	0.6	0
192	Cost-Effectiveness of Endoscopic Therapy for Barrett's Esophagus. , 2009, , 165-185.		0
193	Infliximab vs. Adalimumab for Crohn's disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1266-1267.	1.9	1
194	S1170 The Effect of Virtual Colonoscopy On Colorectal Cancer Screening in a Nonadherent Population. <i>Gastroenterology</i> , 2008, 134, A-193.	0.6	0
195	Surgical Versus Endoscopic Therapy for Barrett's Esophagus with Intramucosal Neoplasia: Determinants of Treatment Modality in a Tertiary Referral Center. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB177.	0.5	0
196	Treatment of Barrett's Esophagus With High-Grade Dysplasia or Cancer: Predictors of Surgical Versus Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1206-1211.	2.4	28
197	Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1179-1187.	1.1	25
198	Patient Preferences for the Chemoprevention of Esophageal Adenocarcinoma in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 2432-2442.	0.2	17

#	ARTICLE	IF	CITATIONS
199	Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis. <i>Radiology</i> , 2008, 248, 169-178.	3.6	71
200	Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis. <i>American Journal of Roentgenology</i> , 2008, 191, 1308-1319.	1.0	17
201	How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2008, 5, 140-141.	1.7	0
202	Esophageal Capsule Endoscopy for Barrett's Esophagus Screening: A Hard Pill to Swallow?. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 307-309.	2.4	3
203	The Management of Small Polyps Found by Virtual Colonoscopy: Results of a Decision Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 237-244.	2.4	63
204	Microsatellite Instability is Frequently Observed in Rectal Cancer and Influenced by Neoadjuvant Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1584.	0.4	13
205	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1017-1024.	2.4	130
206	Quality of life in patients with various Barrett's esophagus associated health states. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 45.	1.0	18
207	Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1052-1063.	0.9	36
208	What is the clinical importance of small polyps with regard to colorectal cancer screening?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 488-489.	1.7	8
209	Patient Preferences for the Management of High-Grade Dysplasia in Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2005, 50, 116-125.	1.1	15
210	Analysis of Aspirin-Associated Risks in Healthy Individuals. <i>Annals of Pharmacotherapy</i> , 2005, 39, 51-57.	0.9	6
211	Correlation of Polyp Number and Family History of Colon Cancer With Germline Mutations. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1022-1028.	2.4	59
212	The Effect of Prior Colonic Imaging on Endoscopic Productivity: Potential Impact of Computed Tomographic Colonography. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1124-1127.	2.4	7
213	Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus. <i>Journal of the National Cancer Institute</i> , 2004, 96, 316-325.	3.0	67
214	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. <i>Cancer</i> , 2004, 101, 189-197.	2.0	18
215	An analysis of the potential impact of computed tomographic colonography (virtual colonoscopy) on colonoscopy demand. <i>Gastroenterology</i> , 2004, 127, 1312-1321.	0.6	47
216	Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1273-1283.	1.1	74

#	ARTICLE	IF	CITATIONS
217	Screening first degree relatives of patients with Celiac Disease. <i>Gastroenterology</i> , 2003, 124, A419.	0.6	0
218	Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. <i>Gastroenterology</i> , 2003, 124, A240.	0.6	0
219	Digital subtraction bowel cleansing (DSBC) in CT colonography (CTC): Experience in 70 patients. <i>Gastroenterology</i> , 2003, 124, A114.	0.6	2
220	Hp eradication rates and symptoms in patients with proven peptic ulcers. <i>American Journal of Gastroenterology</i> , 2000, 95, 2454-2454.	0.2	0
221	<i>Helicobacter pylori</i> eradication rates and symptoms in patients with endoscopically diagnosed peptic ulcers. <i>Gastroenterology</i> , 2000, 118, A1248.	0.6	0
222	PREVALENCE OF ANTIBODY TO HUMAN HERPESVIRUS 6 AMONG BLOOD DONORS INFECTED WITH HIV. <i>Lancet, The</i> , 1988, 332, 1146.	6.3	28
223	Tissue scale agent-based simulation of premalignant progressions in Barrett's esophagus. <i>Simulation</i> , 0, , 003754972110400.	1.1	1